SynthesisInfection2014
Treatment of recurrent Clostridium difficile infection: a systematic review.
Synthesis in Infection, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review.PloS one · 2014Pooled it
- Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection withGut · 2019Trial
- Gemcitabine-Induced Pseudocellulitis in Metastatic Pancreatic Cancer.Journal of Brown hospital medicine · 2026Article
- Biochemical characterization and X-ray structural and mutagenic analyses of the putative autolysin CdCwlT33800 catalytic domain fromApplied and environmental microbiology · 2025Article
- Guidelines for Antibiotics Prescription in Critically Ill Patients.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- Probiotics for Prevention and Treatment of Clostridium difficile Infection.Advances in experimental medicine and biology · 2024Article
- Clostridioides difficile Infection in Children: Recent Updates on Epidemiology, Diagnosis, Therapy.Pediatrics · 2023Review
- Biochemical Characterizations of the Putative Endolysin Ecd09610 Catalytic Domain fromAntibiotics (Basel, Switzerland) · 2022Article
- Characterization of an Endolysin TargetingInternational journal of molecular sciences · 2021Article
- Factors that influence clinical efficacy of live biotherapeutic products.European journal of medical research · 2021Review
- Guidelines for Antibiotic Prescription in Intensive Care Unit.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2019Article
- Pre-colonization with the commensal fungus Candida albicans reduces murine susceptibility to Clostridium difficile infection.Gut microbes · 2018Article
- Extended duration vancomycin in recurrentTherapeutic advances in infectious disease · 2018Review
- Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review.Infectious diseases and therapy · 2018Review
- Treatment of recurrentGastroenterology report · 2018Review
- Faecal microbiota transplantation: a regulatory hurdle?BMC gastroenterology · 2017Review
- Review
- Fecal Microbiota Therapy for Clostridium difficile Infection: A Health Technology Assessment.Ontario health technology assessment series · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundClostridium difficile infection (CDI) recurs in nearly one-third of patients who develop an initial infection. Recurrent CDI (RCDI) is associated with considerable morbidity, mortality, and cost. Treatment for RCDI has not been not well examined.
methodsA systematic review.
resultsSixty-four articles were identified evaluating eight different treatment approaches: metronidazole, vancomycin, fidaxomicin, nitazoxanide, rifampin, immunoglobulins, probiotics, and fecal bacteriotherapy. The meta-analysis found vancomycin to have a similar efficacy to metronidazole, although studies used varying doses and durations of therapy. Fidaxomicin was slightly more efficacious than vancomycin, though the number of studies was small. Good evidence for probiotics was limited. Fecal bacteriotherapy was found to be highly efficacious in a single randomized trial.
conclusionMetronidazole and vancomycin have good evidence for use in RCDI but heterogeneity in treatment duration and dose precludes robust conclusions. Fidaxomicin may have a role in treatment, but evidence is limited to subgroup analyses. Fecal bacteriotherapy was the most efficacious. Saccharomyces boulardii may have a role as adjunctive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.